Title: Adherence to infliximab treatment in patients with immune-mediated inflammatory
diseases from a Referral Center in Brazil: A cohort study
Version: 2 Date: 02 Aug 2024
Reviewer:  Lucian Negreanu
Reviewer's report:
This is a single center experience with adherence to Ifx therapy in IMID.
Article is well written, comprehensive discussion and good motivation of the results.(patient
less adherent most frequently due to difficulty to arrive at the perfusion point).
We have the results at one year with very good adherence especially for rheumatology and
dermatology.
It can be an interesting experience for physicians in their decision to choose the therapy.
Title: Adherence to infliximab treatment in patients with immune-mediated inflammatory
diseases from a Referral Center in Brazil: A cohort study
Version: 2 Date: 02 Aug 2024
Reviewer:  Lucian Negreanu
Reviewer's report:
This is a single center experience with adherence to Ifx therapy in IMID.
Article is well written, comprehensive discussion and good motivation of the results.(patient
less adherent most frequently due to difficulty to arrive at the perfusion point).
We have the results at one year with very good adherence especially for rheumatology and
dermatology.
It can be an interesting experience for physicians in their decision to choose the therapy.
Please review this paper.
user
Title: Adherence to infliximab treatment in patients with immune-mediated inflammatory
diseases from a Referral Center in Brazil: A cohort study
Version: 2 Date: 02 Aug 2024
Reviewer:  Lucian Negreanu
Reviewer's report:
This is a single center experience with adherence to Ifx therapy in IMID.
Article is well written, comprehensive discussion and good motivation of the results.(patient
less adherent most frequently due to difficulty to arrive at the perfusion point).
We have the results at one year with very good adherence especially for rheumatology and
dermatology.
It can be an interesting experience for physicians in their decision to choose the therapy.
assistant